APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncology Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oncology Biosimilars Market Analysis and Forecast 2026-2032

21 December 2025194 pages

Choose your research edition.

Industry ResearchOncology Biosimilars Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncology Biosimilars Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Oncology Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncology Biosimilars Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncology Biosimilars Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Oncology Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Oncology Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oncology Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oncology Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oncology Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Oncology Biosimilars include Teva Pharmaceutical Industries Ltd, Sandoz International, Pfizer, STADA Arzneimittel AG, Intas Pharmaceuticals, Dr. Reddy’s Laboratories, Celltrion, Biocon and BIOCAD, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Oncology Biosimilars, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oncology Biosimilars, also provides the revenue of main regions and countries. Of the upcoming market potential for Oncology Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oncology Biosimilars revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oncology Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oncology Biosimilars revenue, projected growth trends, production technology, application and end-user industry.

Oncology Biosimilars Segment by Company

Teva Pharmaceutical Industries Ltd

Sandoz International

Pfizer

STADA Arzneimittel AG

Intas Pharmaceuticals

Dr. Reddy’s Laboratories

Celltrion

Biocon

BIOCAD

Apotex

Oncology Biosimilars Segment by Type

Hematopoietic Agents

Monoclonal Antibody

G-CSF

Others

Oncology Biosimilars Segment by Application

Hospital Pharmacy

Online Pharmacy

Retail Pharmacies

Oncology Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncology Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oncology Biosimilars in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oncology Biosimilars company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Biosimilars revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oncology Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Hematopoietic Agents Major Player Table 3. Monoclonal Antibody Major Player Table 4. G-CSF Major Player Table 5. Others Major Player Table 6. Global Oncology Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Pharmacy Major Player Table 8. Online Pharmacy Major Player Table 9. Retail Pharmacies Major Player Table 10. Oncology Biosimilars Industry Trends Table 11. Oncology Biosimilars Industry Drivers Table 12. Oncology Biosimilars Industry Opportunities and Challenges Table 13. Oncology Biosimilars Industry Restraints Table 14. Global Oncology Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Oncology Biosimilars Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Oncology Biosimilars Market Share by Region (2021-2026) Table 17. Global Oncology Biosimilars Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Oncology Biosimilars Market Share by Region (2027-2032) Table 19. Global Oncology Biosimilars Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Oncology Biosimilars Revenue Market Share by Players (2021-2026) Table 21. Global Oncology Biosimilars Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Oncology Biosimilars Key Players Headquarters & Area Served Table 23. Global Oncology Biosimilars Players, Product Type & Application Table 24. Global Oncology Biosimilars Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Oncology Biosimilars by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Oncology Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Oncology Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Oncology Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Oncology Biosimilars Revenue Market Share by Type (2021-2026) Table 31. Global Oncology Biosimilars Revenue Market Share by Type (2027-2032) Table 32. Global Oncology Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Oncology Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Oncology Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Oncology Biosimilars Revenue Market Share by Application (2021-2026) Table 36. Global Oncology Biosimilars Revenue Market Share by Application (2027-2032) Table 37. Teva Pharmaceutical Industries Ltd Company Information Table 38. Teva Pharmaceutical Industries Ltd Business Overview Table 39. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Portfolio Table 41. Teva Pharmaceutical Industries Ltd Recent Development Table 42. Sandoz International Company Information Table 43. Sandoz International Business Overview Table 44. Sandoz International Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Sandoz International Oncology Biosimilars Product Portfolio Table 46. Sandoz International Recent Development Table 47. Pfizer Company Information Table 48. Pfizer Business Overview Table 49. Pfizer Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Pfizer Oncology Biosimilars Product Portfolio Table 51. Pfizer Recent Development Table 52. STADA Arzneimittel AG Company Information Table 53. STADA Arzneimittel AG Business Overview Table 54. STADA Arzneimittel AG Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. STADA Arzneimittel AG Oncology Biosimilars Product Portfolio Table 56. STADA Arzneimittel AG Recent Development Table 57. Intas Pharmaceuticals Company Information Table 58. Intas Pharmaceuticals Business Overview Table 59. Intas Pharmaceuticals Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Intas Pharmaceuticals Oncology Biosimilars Product Portfolio Table 61. Intas Pharmaceuticals Recent Development Table 62. Dr. Reddy’s Laboratories Company Information Table 63. Dr. Reddy’s Laboratories Business Overview Table 64. Dr. Reddy’s Laboratories Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Dr. Reddy’s Laboratories Oncology Biosimilars Product Portfolio Table 66. Dr. Reddy’s Laboratories Recent Development Table 67. Celltrion Company Information Table 68. Celltrion Business Overview Table 69. Celltrion Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Celltrion Oncology Biosimilars Product Portfolio Table 71. Celltrion Recent Development Table 72. Biocon Company Information Table 73. Biocon Business Overview Table 74. Biocon Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Biocon Oncology Biosimilars Product Portfolio Table 76. Biocon Recent Development Table 77. BIOCAD Company Information Table 78. BIOCAD Business Overview Table 79. BIOCAD Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. BIOCAD Oncology Biosimilars Product Portfolio Table 81. BIOCAD Recent Development Table 82. Apotex Company Information Table 83. Apotex Business Overview Table 84. Apotex Oncology Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Apotex Oncology Biosimilars Product Portfolio Table 86. Apotex Recent Development Table 87. North America Oncology Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 88. North America Oncology Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 89. North America Oncology Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 90. North America Oncology Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 91. North America Oncology Biosimilars Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. North America Oncology Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 93. North America Oncology Biosimilars Revenue by Country (US$ Million) & (2027-2032) Table 94. Europe Oncology Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 95. Europe Oncology Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 96. Europe Oncology Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 97. Europe Oncology Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 98. Europe Oncology Biosimilars Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Europe Oncology Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 100. Europe Oncology Biosimilars Revenue by Country (US$ Million) & (2027-2032) Table 101. China Oncology Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 102. China Oncology Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 103. China Oncology Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 104. China Oncology Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Oncology Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 106. Asia Oncology Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 107. Asia Oncology Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 108. Asia Oncology Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Oncology Biosimilars Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Asia Oncology Biosimilars Revenue by Region (US$ Million) & (2021-2026) Table 111. Asia Oncology Biosimilars Revenue by Region (US$ Million) & (2027-2032) Table 112. SAMEA Oncology Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 113. SAMEA Oncology Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 114. SAMEA Oncology Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 115. SAMEA Oncology Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 116. SAMEA Oncology Biosimilars Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. SAMEA Oncology Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 118. SAMEA Oncology Biosimilars Revenue by Country (US$ Million) & (2027-2032) Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Oncology Biosimilars Image Figure 2. Global Oncology Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncology Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 4. Hematopoietic Agents Image Figure 5. Monoclonal Antibody Image Figure 6. G-CSF Image Figure 7. Others Image Figure 8. Global Oncology Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Oncology Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Pharmacy Image Figure 11. Online Pharmacy Image Figure 12. Retail Pharmacies Image Figure 13. Global Oncology Biosimilars Market Size (US$ Million) & (2021-2032) Figure 14. Global Oncology Biosimilars Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Oncology Biosimilars Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Oncology Biosimilars Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Oncology Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Oncology Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Oncology Biosimilars Revenue Market Share by Type (2021-2032) Figure 21. Global Oncology Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Oncology Biosimilars Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Oncology Biosimilars Revenue Market Share by Application (2021-2032) Figure 24. North America Oncology Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Oncology Biosimilars Revenue Share by Type (2021-2032) Figure 26. North America Oncology Biosimilars Revenue Share by Application (2021-2032) Figure 27. North America Oncology Biosimilars Revenue Share by Country (2021-2032) Figure 28. United States Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Oncology Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Oncology Biosimilars Revenue Share by Type (2021-2032) Figure 33. Europe Oncology Biosimilars Revenue Share by Application (2021-2032) Figure 34. Europe Oncology Biosimilars Revenue Share by Country (2021-2032) Figure 35. Germany Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Oncology Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Oncology Biosimilars Revenue Share by Type (2021-2032) Figure 45. China Oncology Biosimilars Revenue Share by Application (2021-2032) Figure 46. Asia Oncology Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Oncology Biosimilars Revenue Share by Type (2021-2032) Figure 48. Asia Oncology Biosimilars Revenue Share by Application (2021-2032) Figure 49. Asia Oncology Biosimilars Revenue Share by Region (2021-2032) Figure 50. Japan Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Oncology Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Oncology Biosimilars Revenue Share by Type (2021-2032) Figure 58. SAMEA Oncology Biosimilars Revenue Share by Application (2021-2032) Figure 59. SAMEA Oncology Biosimilars Revenue Share by Country (2021-2032) Figure 60. Brazil Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Oncology Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Hematopoietic Agents
  • Monoclonal Antibody
  • G-CSF
  • Others
Applications
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacies
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International
  • Pfizer
  • STADA Arzneimittel AG
  • Intas Pharmaceuticals
  • Dr. Reddy’s Laboratories
  • Celltrion
  • Biocon
  • BIOCAD
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oncology Biosimilars Market by Type
  3. 1.2.1 Global Oncology Biosimilars Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Hematopoietic Agents
  5. 1.2.3 Monoclonal Antibody
  6. 1.2.4 G-CSF
  7. 1.2.5 Others
  8. 1.3 Oncology Biosimilars Market by Application
  9. 1.3.1 Global Oncology Biosimilars Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital Pharmacy
  11. 1.3.3 Online Pharmacy
  12. 1.3.4 Retail Pharmacies
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Oncology Biosimilars Market Dynamics
  1. 2.1 Oncology Biosimilars Industry Trends
  2. 2.2 Oncology Biosimilars Industry Drivers
  3. 2.3 Oncology Biosimilars Industry Opportunities and Challenges
  4. 2.4 Oncology Biosimilars Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oncology Biosimilars Market Perspective (2021-2032)
  2. 3.2 Global Oncology Biosimilars Growth Trends by Region
  3. 3.2.1 Global Oncology Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oncology Biosimilars Market Size by Region (2021-2026)
  5. 3.2.3 Global Oncology Biosimilars Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oncology Biosimilars Revenue by Players
  2. 4.1.1 Global Oncology Biosimilars Revenue by Players (2021-2026)
  3. 4.1.2 Global Oncology Biosimilars Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oncology Biosimilars Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oncology Biosimilars Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oncology Biosimilars Key Players Headquarters & Area Served
  7. 4.4 Global Oncology Biosimilars Players, Product Type & Application
  8. 4.5 Global Oncology Biosimilars Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oncology Biosimilars Market CR5 and HHI
  11. 4.6.3 2025 Oncology Biosimilars Tier 1, Tier 2, and Tier 3
5 Oncology Biosimilars Market Size by Type
  1. 5.1 Global Oncology Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oncology Biosimilars Revenue by Type (2021-2032)
  3. 5.3 Global Oncology Biosimilars Revenue Market Share by Type (2021-2032)
6 Oncology Biosimilars Market Size by Application
  1. 6.1 Global Oncology Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oncology Biosimilars Revenue by Application (2021-2032)
  3. 6.3 Global Oncology Biosimilars Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva Pharmaceutical Industries Ltd
  2. 7.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 7.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 7.1.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Portfolio
  6. 7.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 7.2 Sandoz International
  8. 7.2.1 Sandoz International Company Information
  9. 7.2.2 Sandoz International Business Overview
  10. 7.2.3 Sandoz International Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sandoz International Oncology Biosimilars Product Portfolio
  12. 7.2.5 Sandoz International Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Oncology Biosimilars Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 STADA Arzneimittel AG
  20. 7.4.1 STADA Arzneimittel AG Company Information
  21. 7.4.2 STADA Arzneimittel AG Business Overview
  22. 7.4.3 STADA Arzneimittel AG Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  23. 7.4.4 STADA Arzneimittel AG Oncology Biosimilars Product Portfolio
  24. 7.4.5 STADA Arzneimittel AG Recent Developments
  25. 7.5 Intas Pharmaceuticals
  26. 7.5.1 Intas Pharmaceuticals Company Information
  27. 7.5.2 Intas Pharmaceuticals Business Overview
  28. 7.5.3 Intas Pharmaceuticals Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Intas Pharmaceuticals Oncology Biosimilars Product Portfolio
  30. 7.5.5 Intas Pharmaceuticals Recent Developments
  31. 7.6 Dr. Reddy’s Laboratories
  32. 7.6.1 Dr. Reddy’s Laboratories Company Information
  33. 7.6.2 Dr. Reddy’s Laboratories Business Overview
  34. 7.6.3 Dr. Reddy’s Laboratories Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Dr. Reddy’s Laboratories Oncology Biosimilars Product Portfolio
  36. 7.6.5 Dr. Reddy’s Laboratories Recent Developments
  37. 7.7 Celltrion
  38. 7.7.1 Celltrion Company Information
  39. 7.7.2 Celltrion Business Overview
  40. 7.7.3 Celltrion Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Celltrion Oncology Biosimilars Product Portfolio
  42. 7.7.5 Celltrion Recent Developments
  43. 7.8 Biocon
  44. 7.8.1 Biocon Company Information
  45. 7.8.2 Biocon Business Overview
  46. 7.8.3 Biocon Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Biocon Oncology Biosimilars Product Portfolio
  48. 7.8.5 Biocon Recent Developments
  49. 7.9 BIOCAD
  50. 7.9.1 BIOCAD Company Information
  51. 7.9.2 BIOCAD Business Overview
  52. 7.9.3 BIOCAD Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  53. 7.9.4 BIOCAD Oncology Biosimilars Product Portfolio
  54. 7.9.5 BIOCAD Recent Developments
  55. 7.10 Apotex
  56. 7.10.1 Apotex Company Information
  57. 7.10.2 Apotex Business Overview
  58. 7.10.3 Apotex Oncology Biosimilars Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Apotex Oncology Biosimilars Product Portfolio
  60. 7.10.5 Apotex Recent Developments
8 North America
  1. 8.1 North America Oncology Biosimilars Revenue (2021-2032)
  2. 8.2 North America Oncology Biosimilars Revenue by Type (2021-2032)
  3. 8.2.1 North America Oncology Biosimilars Revenue by Type (2021-2026)
  4. 8.2.2 North America Oncology Biosimilars Revenue by Type (2027-2032)
  5. 8.3 North America Oncology Biosimilars Revenue Share by Type (2021-2032)
  6. 8.4 North America Oncology Biosimilars Revenue by Application (2021-2032)
  7. 8.4.1 North America Oncology Biosimilars Revenue by Application (2021-2026)
  8. 8.4.2 North America Oncology Biosimilars Revenue by Application (2027-2032)
  9. 8.5 North America Oncology Biosimilars Revenue Share by Application (2021-2032)
  10. 8.6 North America Oncology Biosimilars Revenue by Country
  11. 8.6.1 North America Oncology Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oncology Biosimilars Revenue by Country (2021-2026)
  13. 8.6.3 North America Oncology Biosimilars Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oncology Biosimilars Revenue (2021-2032)
  2. 9.2 Europe Oncology Biosimilars Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oncology Biosimilars Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oncology Biosimilars Revenue by Type (2027-2032)
  5. 9.3 Europe Oncology Biosimilars Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oncology Biosimilars Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oncology Biosimilars Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oncology Biosimilars Revenue by Application (2027-2032)
  9. 9.5 Europe Oncology Biosimilars Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oncology Biosimilars Revenue by Country
  11. 9.6.1 Europe Oncology Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oncology Biosimilars Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oncology Biosimilars Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oncology Biosimilars Revenue (2021-2032)
  2. 10.2 China Oncology Biosimilars Revenue by Type (2021-2032)
  3. 10.2.1 China Oncology Biosimilars Revenue by Type (2021-2026)
  4. 10.2.2 China Oncology Biosimilars Revenue by Type (2027-2032)
  5. 10.3 China Oncology Biosimilars Revenue Share by Type (2021-2032)
  6. 10.4 China Oncology Biosimilars Revenue by Application (2021-2032)
  7. 10.4.1 China Oncology Biosimilars Revenue by Application (2021-2026)
  8. 10.4.2 China Oncology Biosimilars Revenue by Application (2027-2032)
  9. 10.5 China Oncology Biosimilars Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oncology Biosimilars Revenue (2021-2032)
  2. 11.2 Asia Oncology Biosimilars Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oncology Biosimilars Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oncology Biosimilars Revenue by Type (2027-2032)
  5. 11.3 Asia Oncology Biosimilars Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oncology Biosimilars Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oncology Biosimilars Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oncology Biosimilars Revenue by Application (2027-2032)
  9. 11.5 Asia Oncology Biosimilars Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oncology Biosimilars Revenue by Country
  11. 11.6.1 Asia Oncology Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oncology Biosimilars Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oncology Biosimilars Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oncology Biosimilars Revenue (2021-2032)
  2. 12.2 SAMEA Oncology Biosimilars Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oncology Biosimilars Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oncology Biosimilars Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oncology Biosimilars Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oncology Biosimilars Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oncology Biosimilars Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oncology Biosimilars Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oncology Biosimilars Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oncology Biosimilars Revenue by Country
  11. 12.6.1 SAMEA Oncology Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oncology Biosimilars Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oncology Biosimilars Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst